Keith J. Dreyer & James M. Hillis

Jun 4, 2026

The FDA’s AI Double-Talk

It’s budget season in Washington, and the Trump Administration’s FY2027 FDA request contains a welcome idea: a Clinical Trial Notification Pathway, a risk-based,...